Table 2. Impact of mutated CXCR4 on BTKi... | American Society of Hematology

Table 2.

Impact of mutated CXCR4 on BTKi activity for ibrutinib and zanubrutinib in WM

Study	Patient population	Agent(s)	Time to major response (CXCR^Mut vs CXCR4^WT)	MRR (%) (CXCR^Mut vs CXCR4^WT)	≥VGPR rate (%) (CXCR^Mut vs CXCR4^WT)	PFS (%) (CXCR^Mut vs CXCR4^WT)
Pivotal study³⁹	R/R	Ibrutinib	4.7 vs 1.8 mo	68 vs 97	9 vs 47	38 vs 70 (60 mo)
INNOVATE arm C⁴⁰	R/R	Ibrutinib	3.6 vs 1.0 mo	71 vs 88	14 vs 41	18 mo vs NR (60 mo)
Phase 2⁴¹	TN	Ibrutinib	7.3 vs 1.8 mo	78 vs 94	14 vs 44	59 vs 92 (48 mo)
INNOVATE arms A, B⁴²	TN, R/R	Ibrutinib Rituximab	3 vs 2 mo	77 vs 81	23 vs 41	63 vs 72 (54 mo)
Phase 2⁴⁹	R/R	Zanubrutinib	N/A	91 vs 87	27 vs 59	∼90 vs ∼78 (42 mo)
ASPEN cohort 1⁴⁴	TN, R/R	Ibrutinib	6.6 vs 2.8 mo	65 vs 85	10 vs 31	49 vs 75 (42 mo)
ASPEN cohort 1⁴⁴	TN, R/R	Zanubrutinib	3.4 vs 2.8 mo	79 vs 83	21 vs 45	73 vs 81 (42 mo)

Study	Patient population	Agent(s)	Time to major response (CXCR^Mut vs CXCR4^WT)	MRR (%) (CXCR^Mut vs CXCR4^WT)	≥VGPR rate (%) (CXCR^Mut vs CXCR4^WT)	PFS (%) (CXCR^Mut vs CXCR4^WT)
Pivotal study³⁹	R/R	Ibrutinib	4.7 vs 1.8 mo	68 vs 97	9 vs 47	38 vs 70 (60 mo)
INNOVATE arm C⁴⁰	R/R	Ibrutinib	3.6 vs 1.0 mo	71 vs 88	14 vs 41	18 mo vs NR (60 mo)
Phase 2⁴¹	TN	Ibrutinib	7.3 vs 1.8 mo	78 vs 94	14 vs 44	59 vs 92 (48 mo)
INNOVATE arms A, B⁴²	TN, R/R	Ibrutinib Rituximab	3 vs 2 mo	77 vs 81	23 vs 41	63 vs 72 (54 mo)
Phase 2⁴⁹	R/R	Zanubrutinib	N/A	91 vs 87	27 vs 59	∼90 vs ∼78 (42 mo)
ASPEN cohort 1⁴⁴	TN, R/R	Ibrutinib	6.6 vs 2.8 mo	65 vs 85	10 vs 31	49 vs 75 (42 mo)
ASPEN cohort 1⁴⁴	TN, R/R	Zanubrutinib	3.4 vs 2.8 mo	79 vs 83	21 vs 45	73 vs 81 (42 mo)

Comparisons listed are for patients with MYD88 mutation.

Abbreviations are explained in Table 1.